Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates

Cell Reports

Volumn 18, Issue 9, 2017, Pages 2175-2188

  Saunders, Kevin O ^a   Nicely, Nathan I ^a   Wiehe, Kevin ^a   Bonsignori, Mattia ^a   Meyerhoff, R Ryan ^a   Parks, Robert ^a   Walkowicz, William E ^b   Aussedat, Baptiste ^b   Wu, Nelson R ^a   Cai, Fangping ^a   Vohra, Yusuf ^b   Park, Peter K ^b   Eaton, Amanda ^a   Go, Eden P ^f   Sutherland, Laura L ^a   Scearce, Richard M ^a   Barouch, Dan H ⁱ   Zhang, Ruijun ^a   Von Holle, Tarra ^a   Overman, R Glenn ^a   Anasti, Kara ^a   Sanders, Rogier W ^h   Moody, M Anthony ^a   Kepler, Thomas B ^d   Korber, Bette ^e   Desaire, Heather ^f   Santra, Sampa ^c   Letvin, Norman L ^c   Nabel, Gary J ^g   Montefiori, David C ^a   Tomaras, Georgia D ^a   Liao, Hua Xin ^a   Alam, S Munir ^a   Danishefsky, Samuel J ^b   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f UNIVERSITY OF KANSAS   (United States)

^g SANOFI   (United States)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

glycan; HIV; long term immunization; V3 glycan; vaccination

Indexed keywords

AMINO ACID; EPITOPE; GLYCAN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MANNOSE; MANNOSE OLIGOSACCHARIDE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; POLYSACCHARIDE; VACCINE; VIRUS ENVELOPE PROTEIN;

ARTICLE; BINDING SITE; CELL SELECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOASSAY; MACACA; NEXT GENERATION SEQUENCING; NONHUMAN; PRIMATE; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; VACCINATION; ANIMAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING SITES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; MACACA MULATTA; MANNOSE; POLYSACCHARIDES; PRIMATES; VACCINES;

EID: 85014123206     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.02.003     Document Type: Article

References (81)

1. Agrawal-Gamse, C., Luallen, R.J., Liu, B., Fu, H., Lee, F.H., Geng, Y., Doms, R.W., Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J. Virol. 85 (2011), 470–480.
2. Alam, S.M., Dennison, S.M., Aussedat, B., Vohra, Y., Park, P.K., Fernández-Tejada, A., Stewart, S., Jaeger, F.H., Anasti, K., Blinn, J.H., et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc. Natl. Acad. Sci. 110 (2013), 18214–18219.
3. Astronomo, R.D., Lee, H.K., Scanlan, C.N., Pantophlet, R., Huang, C.Y., Wilson, I.A., Blixt, O., Dwek, R.A., Wong, C.H., Burton, D.R., A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J. Virol. 82 (2008), 6359–6368.
4. Astronomo, R.D., Kaltgrad, E., Udit, A.K., Wang, S.K., Doores, K.J., Huang, C.Y., Pantophlet, R., Paulson, J.C., Wong, C.H., Finn, M.G., Burton, D.R., Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem. Biol. 17 (2010), 357–370.
5. Blattner, C., Lee, J.H., Sliepen, K., Derking, R., Falkowska, E., de la Peña, A.T., Cupo, A., Julien, J.P., van Gils, M., Lee, P.S., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40 (2014), 669–680.
6. Bonomelli, C., Doores, K.J., Dunlop, D.C., Thaney, V., Dwek, R.A., Burton, D.R., Crispin, M., Scanlan, C.N., The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE, 6, 2011, e23521.
7. Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M.G., Ozorowski, G., Chuang, G.Y., Schramm, C.A., Wiehe, K., et al., NISC Comparative Sequencing Program. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell 165 (2016), 449–463.
8. Bowers, P.M., Verdino, P., Wang, Z., da Silva Correia, J., Chhoa, M., Macondray, G., Do, M., Neben, T.Y., Horlick, R.A., Stanfield, R.L., et al. Nucleotide insertions and deletions complement point mutations to massively expand the diversity created by somatic hypermutation of antibodies. J. Biol. Chem. 289 (2014), 33557–33567.
9. Bradley, T., Fera, D., Bhiman, J., Eslamizar, L., Lu, X., Anasti, K., Zhang, R., Sutherland, L.L., Scearce, R.M., Bowman, C.M., et al. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 14 (2016), 43–54.
10. Burton, D.R., Ahmed, R., Barouch, D.H., Butera, S.T., Crotty, S., Godzik, A., Kaufmann, D.E., McElrath, M.J., Nussenzweig, M.C., Pulendran, B., et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 12 (2012), 396–407.
11. Calarese, D.A., Scanlan, C.N., Zwick, M.B., Deechongkit, S., Mimura, Y., Kunert, R., Zhu, P., Wormald, M.R., Stanfield, R.L., Roux, K.H., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 (2003), 2065–2071.
12. Corti, D., Lanzavecchia, A., Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31 (2013), 705–742.
13. Crispin, M., Harvey, D.J., Chang, V.T., Yu, C., Aricescu, A.R., Jones, E.Y., Davis, S.J., Dwek, R.A., Rudd, P.M., Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology 16 (2006), 748–756.
14. Crooks, E.T., Tong, T., Chakrabarti, B., Narayan, K., Georgiev, I.S., Menis, S., Huang, X., Kulp, D., Osawa, K., Muranaka, J., et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathog., 11, 2015, e1004932.
15. de Taeye, S.W., Ozorowski, G., Torrents de la Peña, A., Guttman, M., Julien, J.P., van den Kerkhof, T.L., Burger, J.A., Pritchard, L.K., Pugach, P., Yasmeen, A., et al. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell 163 (2015), 1702–1715.
16. DeLano, W.L., The PyMOL Molecular Graphics System. 2012, Schrödinger, LLC.
17. Deshaw, M., Pirofski, L.A., Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Clin. Exp. Immunol. 99 (1995), 425–432.
18. Doores, K.J., The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J. 282 (2015), 4679–4691.
19. Doores, K.J., Burton, D.R., Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84 (2010), 10510–10521.
20. Doores, K.J., Bonomelli, C., Harvey, D.J., Vasiljevic, S., Dwek, R.A., Burton, D.R., Crispin, M., Scanlan, C.N., Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. USA 107 (2010), 13800–13805.
21. Doores, K.J., Fulton, Z., Hong, V., Patel, M.K., Scanlan, C.N., Wormald, M.R., Finn, M.G., Burton, D.R., Wilson, I.A., Davis, B.G., A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc. Natl. Acad. Sci. USA 107 (2010), 17107–17112.
22. Doores, K.J., Kong, L., Krumm, S.A., Le, K.M., Sok, D., Laserson, U., Garces, F., Poignard, P., Wilson, I.A., Burton, D.R., Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J. Virol. 89 (2015), 1105–1118.
23. Doria-Rose, N.A., Klein, R.M., Manion, M.M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C.W., Migueles, S.A., Wrammert, J., Ahmed, R., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83 (2009), 188–199.
24. Doria-Rose, N.A., Schramm, C.A., Gorman, J., Moore, P.L., Bhiman, J.N., DeKosky, B.J., Ernandes, M.J., Georgiev, I.S., Kim, H.J., Pancera, M., et al., NISC Comparative Sequencing Program. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
25. Dunlop, D.C., Bonomelli, C., Mansab, F., Vasiljevic, S., Doores, K.J., Wormald, M.R., Palma, A.S., Feizi, T., Harvey, D.J., Dwek, R.A., et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 20 (2010), 812–823.
26. Eggink, D., Melchers, M., Wuhrer, M., van Montfort, T., Dey, A.K., Naaijkens, B.A., David, K.B., Le Douce, V., Deelder, A.M., Kang, K., et al. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401 (2010), 236–247.
27. Escolano, A., Steichen, J.M., Dosenovic, P., Kulp, D.W., Golijanin, J., Sok, D., Freund, N.T., Gitlin, A.D., Oliveira, T., Araki, T., et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 166 (2016), 1445–1458.
28. Fauci, A.S., Marston, H.D., Ending AIDS–is an HIV vaccine necessary?. N. Engl. J. Med. 370 (2014), 495–498.
29. Garces, F., Sok, D., Kong, L., McBride, R., Kim, H.J., Saye-Francisco, K.F., Julien, J.P., Hua, Y., Cupo, A., Moore, J.P., et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159 (2014), 69–79.
30. Garces, F., Lee, J.H., de Val, N., de la Pena, A.T., Kong, L., Puchades, C., Hua, Y., Stanfield, R.L., Burton, D.R., Moore, J.P., et al. Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity 43 (2015), 1053–1063.
31. Go, E.P., Irungu, J., Zhang, Y., Dalpathado, D.S., Liao, H.X., Sutherland, L.L., Alam, S.M., Haynes, B.F., Desaire, H., Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes’ accessibility. J. Proteome Res. 7 (2008), 1660–1674.
32. Go, E.P., Liao, H.X., Alam, S.M., Hua, D., Haynes, B.F., Desaire, H., Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J. Proteome Res. 12 (2013), 1223–1234.
33. Go, E.P., Herschhorn, A., Gu, C., Castillo-Menendez, L., Zhang, S., Mao, Y., Chen, H., Ding, H., Wakefield, J.K., Hua, D., et al. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. J. Virol. 89 (2015), 8245–8257.
34. Gray, E.S., Madiga, M.C., Hermanus, T., Moore, P.L., Wibmer, C.K., Tumba, N.L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al., CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85 (2011), 4828–4840.
35. Hangartner, L., Zinkernagel, R.M., Hengartner, H., Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol. 6 (2006), 231–243.
36. Haynes, B.F., Verkoczy, L., AIDS/HIV. Host controls of HIV neutralizing antibodies. Science 344 (2014), 588–589.
37. Haynes, B.F., Kelsoe, G., Harrison, S.C., Kepler, T.B., B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30 (2012), 423–433.
38. Im, W., Beglov, D., Roux, B., Continuum solvation model: computation of electrostatic forces from numerical solutions to the Poisson-Boltzmann equation. Comput. Phys. Commun. 111 (1998), 59–75.
39. Jo, S., Kim, T., Iyer, V.G., Im, W., CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29 (2008), 1859–1865.
40. Jo, S., Vargyas, M., Vasko-Szedlar, J., Roux, B., Im, W., PBEQ-Solver for online visualization of electrostatic potential of biomolecules. Nucleic Acids Res. 36 (2008), W270–W275.
41. Joyce, J.G., Krauss, I.J., Song, H.C., Opalka, D.W., Grimm, K.M., Nahas, D.D., Esser, M.T., Hrin, R., Feng, M., Dudkin, V.Y., et al. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc. Natl. Acad. Sci. USA 105 (2008), 15684–15689.
42. Julien, J.P., Cupo, A., Sok, D., Stanfield, R.L., Lyumkis, D., Deller, M.C., Klasse, P.J., Burton, D.R., Sanders, R.W., Moore, J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342 (2013), 1477–1483.
43. Kepler, T.B., Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. F1000Res., 2, 2013, 103.
44. Kepler, T.B., Liao, H.X., Alam, S.M., Bhaskarabhatla, R., Zhang, R., Yandava, C., Stewart, S., Anasti, K., Kelsoe, G., Parks, R., et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe 16 (2014), 304–313.
45. Kong, L., Lee, J.H., Doores, K.J., Murin, C.D., Julien, J.P., McBride, R., Liu, Y., Marozsan, A., Cupo, A., Klasse, P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20 (2013), 796–803.
46. Kuraoka, M., Schmidt, A.G., Nojima, T., Feng, F., Watanabe, A., Kitamura, D., Harrison, S.C., Kepler, T.B., Kelsoe, G., Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. Immunity 44 (2016), 542–552.
47. Leonard, C.K., Spellman, M.W., Riddle, L., Harris, R.J., Thomas, J.N., Gregory, T.J., Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265 (1990), 10373–10382.
48. Liao, H.X., Levesque, M.C., Nagel, A., Dixon, A., Zhang, R., Walter, E., Parks, R., Whitesides, J., Marshall, D.J., Hwang, K.K., et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158 (2009), 171–179.
49. Liao, H.X., Lynch, R., Zhou, T., Gao, F., Alam, S.M., Boyd, S.D., Fire, A.Z., Roskin, K.M., Schramm, C.A., Zhang, Z., et al., NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496 (2013), 469–476.
50. Liao, H.X., Tsao, C.Y., Alam, S.M., Muldoon, M., Vandergrift, N., Ma, B.J., Lu, X., Sutherland, L.L., Scearce, R.M., Bowman, C., et al. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J. Virol. 87 (2013), 4185–4201.
51. MacLeod, D.T., Choi, N.M., Briney, B., Garces, F., Ver, L.S., Landais, E., Murrell, B., Wrin, T., Kilembe, W., Liang, C.H., et al., IAVI Protocol C Investigators & The IAVI African HIV Research Network. Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity 44 (2016), 1215–1226.
52. Mascola, J.R., Haynes, B.F., HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254 (2013), 225–244.
53. Mascola, J.R., Montefiori, D.C., The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28 (2010), 413–444.
54. McCoy, L.E., van Gils, M.J., Ozorowski, G., Messmer, T., Briney, B., Voss, J.E., Kulp, D.W., Macauley, M.S., Sok, D., Pauthner, M., et al. Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Rep. 16 (2016), 2327–2338.
55. McLellan, J.S., Pancera, M., Carrico, C., Gorman, J., Julien, J.P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480 (2011), 336–343.
56. Moldt, B., Rakasz, E.G., Schultz, N., Chan-Hui, P.Y., Swiderek, K., Weisgrau, K.L., Piaskowski, S.M., Bergman, Z., Watkins, D.I., Poignard, P., Burton, D.R., Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109 (2012), 18921–18925.
57. Moody, M.A., Yates, N.L., Amos, J.D., Drinker, M.S., Eudailey, J.A., Gurley, T.C., Marshall, D.J., Whitesides, J.F., Chen, X., Foulger, A., et al. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J. Virol. 86 (2012), 7496–7507.
58. Murin, C.D., Julien, J.P., Sok, D., Stanfield, R.L., Khayat, R., Cupo, A., Moore, J.P., Burton, D.R., Wilson, I.A., Ward, A.B., Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J. Virol. 88 (2014), 10177–10188.
59. Pancera, M., Zhou, T., Druz, A., Georgiev, I.S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.Y., Ofek, G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514 (2014), 455–461.
60. Parren, P.W., Burton, D.R., The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77 (2001), 195–262.
61. Pejchal, R., Doores, K.J., Walker, L.M., Khayat, R., Huang, P.S., Wang, S.K., Stanfield, R.L., Julien, J.P., Ramos, A., Crispin, M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334 (2011), 1097–1103.
62. Reeves, P.J., Callewaert, N., Contreras, R., Khorana, H.G., Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. USA 99 (2002), 13419–13424.
63. Sanders, R.W., van Gils, M.J., Derking, R., Sok, D., Ketas, T.J., Burger, J.A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 349, 2015, aac4223.
64. Sather, D.N., Armann, J., Ching, L.K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., Stamatatos, L., Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83 (2009), 757–769.
65. Scanlan, C.N., Offer, J., Zitzmann, N., Dwek, R.A., Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446 (2007), 1038–1045.
66. Scanlan, C.N., Ritchie, G.E., Baruah, K., Crispin, M., Harvey, D.J., Singer, B.B., Lucka, L., Wormald, M.R., Wentworth, P. Jr., Zitzmann, N., et al. Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J. Mol. Biol. 372 (2007), 16–22.
67. Simek, M.D., Rida, W., Priddy, F.H., Pung, P., Carrow, E., Laufer, D.S., Lehrman, J.K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83 (2009), 7337–7348.
68. Simonich, C.A., Williams, K.L., Verkerke, H.P., Williams, J.A., Nduati, R., Lee, K.K., Overbaugh, J., HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant. Cell 166 (2016), 77–87.
69. Sok, D., Pauthner, M., Briney, B., Lee, J.H., Saye-Francisco, K.L., Hsueh, J., Ramos, A., Le, K.M., Jones, M., Jardine, J.G., et al. A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. Immunity 45 (2016), 31–45.
70. Steichen, J.M., Kulp, D.W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R.L., McCoy, L.E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 45 (2016), 483–496.
71. Tian, M., Cheng, C., Chen, X., Duan, H., Cheng, H.L., Dao, M., Sheng, Z., Kimble, M., Wang, L., Lin, S., et al. Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166 (2016), 1471–1484.
72. Volpe, J.M., Cowell, L.G., Kepler, T.B., SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22 (2006), 438–444.
73. Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L., Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al., Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009), 285–289.
74. Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B., Phogat, S.K., Poignard, P., Burton, D.R., A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog., 6, 2010, e1001028.
75. Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.P., Wang, S.K., Ramos, A., Chan-Hui, P.Y., Moyle, M., et al., Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477 (2011), 466–470.
76. Wang, S.K., Liang, P.H., Astronomo, R.D., Hsu, T.L., Hsieh, S.L., Burton, D.R., Wong, C.H., Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl. Acad. Sci. USA 105 (2008), 3690–3695.
77. Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003), 307–312.
78. Wiehe, K., Easterhoff, D., Luo, K., Nicely, N.I., Bradley, T., Jaeger, F.H., Dennison, S.M., Zhang, R., Lloyd, K.E., Stolarchuk, C., et al. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity 41 (2014), 909–918.
79. Zhang, H., Fu, H., Luallen, R.J., Liu, B., Lee, F.H., Doms, R.W., Geng, Y., Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans. Vaccine 33 (2015), 5140–5147.
80. Zhang, R., Verkoczy, L., Wiehe, K., Munir Alam, S., Nicely, N.I., Santra, S., Bradley, T., Pemble, C.W. 4th, Zhang, J., Gao, F., et al. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. Sci. Transl. Med., 8, 2016, 336ra62.
81. Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I.S., Altae-Tran, H.R., Chuang, G.Y., Joyce, M.G., et al., NISC Comparative Sequencing Program. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39 (2013), 245–258.